DHI Group (DHX) Reports In-Line Q4 EPS, Revenues Beat

DHI Group (NYSE: DHX) reported Q4 EPS of $0.06, in-line with the analyst estimate of $0.06. Revenue for the quarter came in at $37.98 million versus the consensus estimate of $37.91 million.

• Revenues were $38.0 million; Ongoing tech-focused revenues1 were unchanged year over year for the first time in nearly 3 years
• Net income was $2.9 million, or $0.06 per diluted share
• Cash flow from operations of $6.2 million; Adjusted EBITDA2 was $8.3 million and Adjusted EBITDA margin2 was 22%

"We ended 2018 with strong momentum, reaching an important inflection point in our business," said Art Zeile, President and Chief Executive Officer of the Company. "We stabilized our ongoing tech-focused revenues1, improved our profitability and made significant progress in delivering against our tech-focused strategy. We put in place a strong, execution-oriented management team and began implementing a culture of customer-focused innovation. We are well positioned to achieve our 2019 strategic growth plan."

Business Outlook

Looking ahead, the Company believes that its ongoing tech-focused business1 will achieve modest year over year revenue growth beginning in the first half of 2019, which should improve as the year progresses. The Company further anticipates that Dice3 will turn to positive year over year revenue growth in the 2019 second half. This year, the Company expects to make further progress on rationalizing its expenses, while at the same time investing prudently for growth, which should enable the Company to maintain its current level of Adjusted EBITDA margin in the first half and gradually begin to increase its margin in the second half. The Company is unable to provide guidance for net income because it cannot reasonably assess the impact of stock-based compensation and income tax expense.

For earnings history and earnings-related data on DHI Group (DHX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Z Squared outlines AI power strategy and Paradox Data acquisition
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c